LEOCLAN Co. Ltd. (JP:7681)
:7681
Top Page
LEOCLAN Co. Ltd.
(7681)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥895.00
▼(-10.41% Downside)
Action:ReiteratedDate:01/14/26
The score is primarily held back by weak recent cash flow and thin/uneven profitability despite a very strong, low-debt balance sheet. Technicals are slightly negative with the stock trading below major moving averages, and valuation is relatively expensive (high P/E) with only a modest dividend yield.
Positive Factors
Low Debt / Strong Balance Sheet
The company’s negligible debt and stable equity base materially reduce financial risk and preserve strategic optionality. Over the medium term this balance-sheet conservatism supports capital allocation flexibility for working-capital needs, selective investment or downturn resilience without reliance on external debt.
Negative Factors
Weak Cash Generation
Negative operating cash flow and consecutive negative free cash flow materially constrain the company’s ability to self-fund growth, pay sustained dividends, or absorb shocks. Persistent cash conversion issues suggest working-capital pressure or investment demands that can erode liquidity and force external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt / Strong Balance Sheet
The company’s negligible debt and stable equity base materially reduce financial risk and preserve strategic optionality. Over the medium term this balance-sheet conservatism supports capital allocation flexibility for working-capital needs, selective investment or downturn resilience without reliance on external debt.
Read all positive factors
LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.41B
Dividend Yield1.67%
Average Volume (3M)4.73K
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue Growth8.51%
EPS Growth12.20%
CountryJP
Employees170
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)-13.46
Shares Outstanding5,922,000
10 Day Avg. Volume9,000
30 Day Avg. Volume4,726
Financial Highlights & Ratios
PEG Ratio3.64
Price to Book (P/B)1.18
Price to Sales (P/S)0.31
P/FCF Ratio-57.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LEOCLAN Co. Ltd. Business Overview & Revenue Model
Company Description
LEOCLAN Co.,Ltd. operates as a medical equipment trading company that meets various medical care, welfare, and health needs. It operates through three segments: Medical Total Solutions Business, Remote Image Diagnosis Service Business, and School ...
LEOCLAN Co. Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
82
Very Positive
Cash Flow
38
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.49B | 19.80B | 26.63B | 29.77B | 26.35B |
| Gross Profit | 2.74B | 2.62B | 2.82B | 3.06B | 2.73B |
| EBITDA | 378.03M | 277.60M | 544.73M | 747.26M | 670.86M |
| Net Income | 152.78M | 136.06M | 271.31M | 437.05M | 390.98M |
Balance Sheet | |||||
| Total Assets | 10.91B | 10.66B | 14.75B | 13.52B | 13.02B |
| Cash, Cash Equivalents and Short-Term Investments | 4.78B | 5.57B | 5.54B | 5.48B | 5.41B |
| Total Debt | 7.19M | 12.57M | 5.67M | 99.82M | 133.54M |
| Total Liabilities | 5.09B | 4.93B | 9.02B | 7.98B | 7.86B |
| Stockholders Equity | 5.63B | 5.57B | 5.57B | 5.38B | 5.03B |
Cash Flow | |||||
| Free Cash Flow | -116.70M | 17.72M | 291.06M | 215.57M | 1.28B |
| Operating Cash Flow | -86.65M | 33.08M | 341.56M | 242.36M | 1.30B |
| Investing Cash Flow | -619.82M | 100.75M | -82.01M | -49.96M | -42.13M |
| Financing Cash Flow | -100.73M | -97.22M | -202.31M | -120.93M | -298.01M |
LEOCLAN Co. Ltd. Technical Analysis
Neutral
999.00
Price Trends
938.62
Negative
969.84
Negative
1016.96
Negative
Market Momentum
-6.93
Negative
52.07
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Neutral. The current price of 999 is above the 20-day moving average (MA) of 888.45, above the 50-day MA of 938.62, and below the 200-day MA of 1016.96, indicating a neutral trend. The MACD of -6.93 indicates Negative momentum. The RSI at 52.07 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7681.
LEOCLAN Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.74B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥5.41B | -19.07 | ― | 1.67% | 8.51% | 12.20% | |
51 Neutral | ¥24.81B | -34.16 | ― | ― | -5.65% | -469.19% | |
49 Neutral | ¥11.35B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.24B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥7.40B | -10.09 | ― | ― | -93.79% | -1332.86% |
* Healthcare Sector Average
JP:7681
LEOCLAN Co. Ltd.
914.00
-76.33
-7.71%
JP:3750
Cytori Cell Research Institute, Inc.
829.00
82.00
10.98%
JP:4599
StemRIM Inc.
307.00
20.00
6.97%
JP:4978
ReproCELL Inc.
176.00
44.00
33.33%
JP:7774
Japan Tissue Engineering Co., Ltd.
611.00
201.00
49.02%
JP:7776
CellSeed Inc.
292.00
-178.00
-37.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.